Traphagen Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Traphagen Investment Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,640	Closed	-$223K	–	133
2021 Q4	$223K	Sell	3,640 -951	-21%	-$65.7K	0.04%	129
2021 Q3	$343K	Sell	4,591 -25,685	-85%	-$2.15M	0.06%	91
2021 Q2	$2.8M	Buy	30,276 +7,844	+35%	+$667K	0.48%	25
2021 Q1	$1.99M	Buy	22,432 +14,982	+201%	+$1.49M	0.37%	32
2020 Q4	$695K	Buy	+7,450	New	+$594K	0.13%	59

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Traphagen Investment Advisors's ARKG Position: Q1 2022 in Review

Traphagen Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 3,640 shares — an estimated $223K sold.

Traphagen Investment Advisors first reported a position in ARKG in Q4 2020 and held it in 5 quarters. The position peaked at $2.8M in Q2 2021. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

Traphagen Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
Traphagen Investment Advisors sold 3,640 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $223K.
Traphagen Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 5 quarters.
Traphagen Investment Advisors's ARK Genomic Revolution ETF position peaked at $2.8M in Q2 2021.
387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Traphagen Investment Advisors's 13F filing for Q1 2022, filed 17 Jun 2024.